| Matthew Thomas Bauer, OD | |
|
401 Phalen Blvd, Saint Paul, MN 55130-5302 | |
| (651) 254-7500 | |
| (651) 254-7557 |
| Full Name | Matthew Thomas Bauer |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 15 Years |
| Location | 401 Phalen Blvd, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316177348 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3168 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthpartners Medical Group | 1759293954 | 1430 |
News Archive
Scientists have long thought that the cells that ultimately give rise to the heart all respond to the same cue before turning into the muscle tissue of this vital organ.
The blood-brain barrier is a network of specialized cells that surrounds the arteries and veins within the brain. It forms a unique gateway that both provides brain cells with the nutrients they require and protects them from potentially harmful compounds.
Cell Therapeutics, Inc. ("CTI") announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February.
Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.
Canadian scientists have discovered a gene that suppresses the growth of many cancerous tumours.
› Verified 8 days ago
| Provider Name | Group Health Plan Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
Scientists have long thought that the cells that ultimately give rise to the heart all respond to the same cue before turning into the muscle tissue of this vital organ.
The blood-brain barrier is a network of specialized cells that surrounds the arteries and veins within the brain. It forms a unique gateway that both provides brain cells with the nutrients they require and protects them from potentially harmful compounds.
Cell Therapeutics, Inc. ("CTI") announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February.
Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.
Canadian scientists have discovered a gene that suppresses the growth of many cancerous tumours.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Thomas Bauer, OD 8170 33rd Ave S # Ms 21110q, Minneapolis, MN 55425-4516 Ph: () - | Matthew Thomas Bauer, OD 401 Phalen Blvd, Saint Paul, MN 55130-5302 Ph: (651) 254-7500 |
News Archive
Scientists have long thought that the cells that ultimately give rise to the heart all respond to the same cue before turning into the muscle tissue of this vital organ.
The blood-brain barrier is a network of specialized cells that surrounds the arteries and veins within the brain. It forms a unique gateway that both provides brain cells with the nutrients they require and protects them from potentially harmful compounds.
Cell Therapeutics, Inc. ("CTI") announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February.
Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.
Canadian scientists have discovered a gene that suppresses the growth of many cancerous tumours.
› Verified 8 days ago
Kennedy Eye Associates Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1790 Lexington Ave N, Saint Paul, MN 55113 Phone: 651-488-6771 Fax: 651-488-5576 | |
Maggie Scott, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1360 University Ave W Ste 106, Saint Paul, MN 55104 Phone: 651-251-0317 | |
Dr. Julie M Blenker, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 261 Ruth St N Ste E, Saint Paul, MN 55119 Phone: 651-739-5173 Fax: 651-739-8907 | |
John Heyen, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1020 Bandana Blvd W, Saint Paul, MN 55108 Phone: 651-241-7000 | |
Dr. Matthew Thomas Hendricks, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7500 | |
Broecker Eye & Optical Optometrist Medicare: Medicare Enrolled Practice Location: 2356 University Ave W, Suite 260, Saint Paul, MN 55114 Phone: 651-645-8124 Fax: 651-645-8125 | |
Dr. David Andrew Spande, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1300 University Ave W, Optical Clinic, Saint Paul, MN 55104 Phone: 651-641-6181 Fax: 651-646-3292 |